{
    "medicine_id": "35187e8775d2d0b1f1ba2382693bf8accb091eef",
    "platform_id": "DB15067",
    "metadata": {
        "name": "Waylivra 285 mg Injection solution",
        "composition": "285 mg Volanesorsen",
        "clinical_particulars": {
            "therapeutic_indications": "Volanesorsen is conditionally approved by the EMA as an adjunct to diet in adults with familial chylomicronemia at high risk for pancreatitis and who have had an inadequate response to diet and triglyceride lowering therapy L16621",
            "contraindications": {
                "disease": "Data regarding overdose are not readily available L16621 However symptoms are likely to involve injection site reactions and constitutional symptomns L16621 Treat patients with symptomatic and supportive care L16621",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Volanesorsen is an antisense oligonucleotide that prevents the translation of apoC III A221296 L16621 It has a long duration of action as it has a half life of 2 weeks L16621 Patients should be counselled regarding the risk of thrombocytopenia raised LDL C levels renal toxicity hepatotoxicity and immunogenicity L16621",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}